B[The concept of innovative drugs rebounded in shock, and Hokuriku Pharmaceutical rose by more than 10%] On September 22, the concept of innovative drugs rebounded in shock, and Beiku Pharmaceutical rose by more than 10%. Previously, Harbin Pharmaceutical Co., Ltd. and Xinhua Pharmaceutical hit the daily limit, and Ruikang Pharmaceutical, Baihua Pharmaceutical, Tailong Pharmaceutical, Jiankai Technology, and Baike Biologics followed suit. On the news, overnight U.S. "cancer vaccine" bull stock Moderna closed up 12.27% on Monday, nearly returning to the year's high hit after the "cancer vaccine" results were released on August 19. B[Inner Mongolia: Accelerate the progress of African swine fever vaccine research and development] On September 11, the General Office of the People's Government of the Inner Mongolia Autonomous Region recently issued the "Action Plan for Accelerating the High-Quality Development of the Biomanufacturing Industry in the Inner Mongolia Autonomous Region." It is proposed to enhance the core competitiveness of biomedicine. Accelerate the establishment and operation of platforms such as the Hohhot Bio-Intelligent Manufacturing Valley, focus on nucleic acid drugs, cell and gene therapy, "AI + medicine" and other characteristic new tracks, and promote the biomedical industry to leapfrog from scale advantages to technology leadership. Consolidate and enhance the global market leading position of animal vaccine products such as foot-and-mouth disease vaccine, accelerate the research and development of African swine fever vaccines, strengthen the promotion and application of new vaccines and multi-linked multivalent vaccines in the region, and improve the prevention and control capabilities of major animal diseases. Leverage the platform advantages of the company's P3 laboratory to accelerate the development and industrialization of cutting-edge products such as mRNA vaccines and mucosal vaccines, and build a world-leading intelligent manufacturing benchmark for animal vaccines. Deepen the secondary development of traditional Chinese medicine (Mongolian medicine), use synthetic biology technology to enable the discovery and efficient preparation of functional components of characteristic Chinese medicine (Mongolian medicine), and create a modern traditional Chinese medicine (Mongolian medicine) industrial system with Inner Mongolian characteristics. B[Inner Mongolia: Accelerate the implementation of key projects in the biomanufacturing industry around key areas such as biofood, biomedicine, and biochemicals] On September 11, the General Office of the People's Government of the Inner Mongolia Autonomous Region recently issued the "Action Plan for Accelerating the High-quality Development of the Biomanufacturing Industry in the Inner Mongolia Autonomous Region." It is proposed to focus on key core technologies to tackle key problems. Focusing on key areas such as bio-food, bio-medicine, and bio-chemical industry, we will accelerate the implementation of key projects in the bio-manufacturing industry. Focusing on the construction of efficient bacterial strains, AI-assisted synthesis, design and transformation of key enzymes, and technological upgrading of existing products, as well as efficient conversion of non-food biomass, new animal vaccine technologies, etc., a number of autonomous region science and technology plan projects will be deployed and implemented. Support enterprises to take the lead in forming innovation consortiums, integrate superior scientific research forces inside and outside the region to carry out collaborative research, and deeply integrate into the national biomanufacturing innovation network. Strengthen the design of the entire industry chain standard system, coordinate and promote the formulation, implementation and application of standards, deploy standard research and development in key links and frontier areas in advance, support enterprises, universities, scientific research institutions, etc. to lead or participate in the formulation and revision of national, industry, group and enterprise standards, and enhance the voice of standards. B[Inner Mongolia: The output value of the biomanufacturing industry will reach more than 100 billion yuan by 2030] On September 11, the General Office of the People's Government of the Inner Mongolia Autonomous Region recently issued the "Action Plan for Accelerating the High-quality Development of the Biomanufacturing Industry in the Inner Mongolia Autonomous Region." It is proposed that by 2030, the scale of the bio-manufacturing industry will continue to expand, the entire industry chain will be gradually built, and it will become an important engine for the development of new productivity in the autonomous region. The output value will reach more than 100 billion yuan, and the number of bio-manufacturing enterprises in the region will be strived to reach more than 500, among which, enterprises above designated size will reach To more than 200 companies, Hutong Chiba Bio-manufacturing Industry Cluster will be supported to create a national-level advanced manufacturing cluster; scientific and technological innovation capabilities will be significantly enhanced, and an important national bio-manufacturing technology innovation node will be basically established. The world's largest lactic acid bacteria and other microbial germplasm resources and genome database will be built to consolidate Traditional advantages include maintaining the international leading level in key indicators such as amino acid fermentation efficiency and veterinary vaccine research and development; industrial upgrading is accelerated, industrialization of key materials such as polylactic acid and bio-based nylon is realized, and the application proportion of non-grain raw materials is gradually increased; market entities and brand cultivation systems are accelerated to build 2- 3 local leading enterprises with a revenue of 5 billion yuan, more than 1 national-level specialized, special and new "little giant" enterprises, more than 5 autonomous region-level specialized, special and new small and medium-sized enterprises, and 2-3 brand products with strong competitiveness in the domestic market, introduce more than 2 well-known domestic and foreign companies to set up production bases. B[This year, the country has free and supportive policies for key groups to receive influenza vaccines] On September 3, Fei Jia, deputy director of the Health and Immunization Department of the National Administration of Disease Control and Prevention, introduced that this year, the country has free and supportive policies for key groups to receive influenza vaccines, through financial funds, employee medical insurance personal account payments, The whole chain of multi-channel financing guarantees, such as labor union funds, supports the vaccination of influenza vaccines for key groups of "one old and one young" in rural areas, employees' medical insurance participants and insured close relatives, and workers in new employment forms, promoting the improvement of vaccination coverage for key groups, and reducing the disease burden and economic burden on the masses. B[The Chinese Center for Disease Control and Prevention released the "Technical Guidelines for Influenza Vaccination in China (2026-2027)"] In order to better promote the vaccination of influenza vaccines in China, the Chinese Center for Disease Control and Prevention organized the National Immunization Program Technical Working Group's Influenza Vaccine Task Force to collect and organize the latest research progress and scientific evidence related to influenza and influenza vaccines at home and abroad, and formed the "Technical Guidelines for Influenza Vaccine Vaccination in China (2026-2027)". Guidelines recommend that all persons 6 months of age and older without contraindications receive influenza vaccination. Combined with the influenza epidemic situation and the prevention and control strategy of multi-disease prevention and control, to reduce the harm of influenza as much as possible, the following key and high-risk groups are given priority for vaccination: medical personnel, including clinical treatment personnel, public health personnel, health quarantine personnel, etc.; elderly people aged 60 and above; people suffering from one or more diseases People with chronic diseases; vulnerable groups and employees in nursing homes, long-term care institutions, welfare homes and other crowded places; children aged 6 months and above to under 5 years old; family members and caregivers of infants under 6 months old; people in key places such as child care institutions, primary and secondary schools, and supervision places; pregnant women.
— All loaded —
